Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor (GPCR) activated by endogenous proteases, in particular, trypsin. Although regulators of G protein signaling (RGS) are known to inhibit GPCR/Gamediated signaling, their specific effects on PAR2 are poorly understood at present. Here, we use a bioluminescence resonance energy transfer technique to investigate whether RGS16 and RGS18 bind PAR2 in live cells to regulate PAR2/Ga i/o -mediated signaling. Notably, we find that RGS16 binds to PAR2 in the presence of Ga i while RGS18 does not interact with PAR2, regardless of the presence of Ga. Both RGS16 and RGS18 inhibit PAR2/ Ga i/o -mediated signaling. To our knowledge, the current study is the first to highlight the effects of RGS proteins on PAR2-mediated signaling.
G protein-coupled receptors (GPCR) possessing seven transmembrane domains transmit extracellular signals, such as hormones and neurotransmitters, to the intracellular environment. Binding of ligands to GPCRs triggers G protein activation through GTP binding of the G protein alpha subunit (Ga), which facilitates the dissociation of G protein heterodimers (Gabc) into Ga and Gbc. Dissociated G protein subunits translocate to their effector molecules to regulate their activity. Ga subunits are classified into several families, specifically, Ga i/o , Ga q/11 , Ga 12/13 , and Ga s .
While most GPCRs are activated by reversible small hydrophilic molecules to elicit a cellular response, activity of protease-activated receptors (PAR), a type of GPCR, is stimulated by endogenous serine proteases, such as thrombin, trypsin, and tryptase, which cleave the extracellular N terminus, resulting in an exposed tethered ligand that binds its own receptor [1] . Four PAR family members have been identified to date, designated PAR1-PAR4. The principal enzyme activator for PAR2 is trypsin while other PARs are mainly stimulated by the coagulation enzyme thrombin. PAR2 couples with Ga i/o , Ga q/11 and Ga 12/13 subtypes, in turn, regulating various signaling pathways, including phospholipases, c-Jun N-terminal kinase, ERK1/2, phosphatidylinositol 3-kinase, adenylyl cyclase, protein kinase C, protein kinase A (PKA), and members of the src family of tyrosine kinases [1, 2] . Activated PAR2 is involved in various (patho)-physiologies, including vasoregulation, cell growth, cancer, inflammation, obesity, and nociception [2, 3] .
The GTPase activity of Ga is accelerated by GTPase-activating proteins (GAP). The most prominent GAP types are members of the regulators of G Abbreviations a2AR, a2-adrenergic receptor; AKAP, A-kinase anchoring protein; BRET, bioluminescence resonance energy transfer; COX-2, cyclooxygenase-2; DMEM, Dulbecco's modified Eagle's medium; GAP, GTPase-activating protein; GPCR, G protein-coupled receptor; Ga, alpha subunit of G protein; PAR2, protease-activated receptor 2; PEI, polyethyleneimine; PKA, protein kinase A; RGS16, regulator of G protein signaling 16; RT-qPCR, quantitative reverse transcription-PCR; TGF-b, transforming growth factor b.
protein signaling (RGS) family that are reported to bind activated Ga (Ga-GTP) and increase GTP hydrolysis [4] . Several isoforms of RGS proteins exist, which are classified into subfamilies based on protein sequence and structure. All RGS proteins contain an RGS domain (~120 amino acids) that binds Ga-GTP and mediates GAP function [5] . RGS16 protein was initially cloned from the retina [6] . Subsequent analyses revealed expression of these proteins in heart, liver, hematopoietic cells, and brain [7] [8] [9] . RGS16 is involved in adaptive immunity, platelet migration, and glucose or fat metabolism. Interacting partners, including Ga i/o , Ga q , and Ga 13 , regulate their downstream effector signals. RGS16 inhibits a 2 -adrenergic receptor (a 2 AR) activity through direct binding [10] . RGS18 proteins have been identified in bone marrow-derived cells, platelets and osteoclasts, and shown to inhibit Ga i -and Ga q -mediated signaling [5, 11] .
G protein-coupled receptors function as scaffolding proteins that interact with several signaling molecules. PAR1 binds transforming growth factor b (TGF-b) receptor II (TGFR-bII) and inhibits dimerization of TGFR-bI/TGFR-bII, which leads to downregulation of TGF-b signaling and modulation of embryonic stem cell differentiation [12] . Gpr161, an orphan GPCR, contains a motif for A-kinase anchoring protein in its C-terminal tail and binds the regulatory subunits of PKA, leading to the modulation of cAMP signaling [13] . GPCRs interact directly or indirectly with RGS proteins as well as Ga. Adrenergic, muscarinic acetylcholine and opioid receptors have been identified as binding factors of RGS proteins [5] . Using a bioluminescence resonance energy transfer (BRET) technique, we previously reported that RGS2 and RGS4 interact with PAR1 in a Ga-dependent manner to regulate PAR1/Ga-mediated signaling [14] . We additionally suggested that RGS8 inhibits PAR1/Ga i/o -mediated signaling by forming a distinct Ga complex [15] .
As specified above, PAR2 is involved in various (patho)physiologies, and therefore, modulation of its activity presents a potential therapeutic approach. Notably, inhibition of PAR2 is reported to decrease tumor progression, pain, and inflammation. Although RGS proteins are clearly involved in inhibition of GPCR function, the mechanisms underlying suppression of PAR2 remain poorly understood at present.
We have previously screened which RGS isoforms interact with PAR2 in the presence of distinct Ga in live cells, employing BRET assay using PAR2-Venus, RGS-Luciferase, and untagged Ga expression plasmids (K. Kim, J. Lee, S. Ghil, unpublished data). Here, we examined the interactions of RGS16 and RGS18 with PAR2 in the presence of Ga subunits. We additionally examined whether RGS16 and RGS18 exert inhibitory effects on PAR/Ga i/o -mediated signaling.
Materials and methods
Plasmid DNA constructs PAR2-Venus (Venus-N1-PAR2), a C-terminal Venustagged plasmid encoding PAR2, was generated by polymerase chain reaction (PCR)-mediated amplification of pcDNA3.1-PAR2 (cDNA Resource Center) using the primer pair 5 0 -AAA AGC TTA TGC GAA GTC TCA GGC 
Measurement of ERK1/2 phosphorylation
The 293T and Neuro2a cells were seeded at a density of 3.5 9 10 5 cells/well into six-well tissue culture dishes and transfected with plasmids, as indicated. Cells were subsequently treated with LIGRLO (PAR2 agonist peptide; Bachem, Bubendorf, Switzerland) and harvested using RIPA buffer, and immunoblotting performed with antibodies against p-ERK1/2 and total ERK1/2 (Cell Signaling Technology, Danvers, MA, USA).
Measurement of cAMP concentrations
293T cells were seeded at a density of 3.5 9 10 5 cells/well into six-well tissue culture dishes and transfected with the indicated plasmids. After 24 h, cells were treated with 10 lM LIGRLO for 4 min and intracellular cAMP levels measured using the cAMP-Glo TM Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Luciferase reporter gene assay
293T cells were seeded at a density of 2 9 10 5 cells/well into six-well tissue culture dishes. Cells were transfected with the indicated combination of plasmids together with 0.1 lg pGL3-E2F4BLuc reporter plasmids containing four consensus E2F binding sites. After 48 h, cells were stimulated with 10 lM LIGRLO for 4 min, and luciferase activities of lysates measured using a Luciferase Assay System (Promega) according to the manufacturer's instructions. Luciferase activity was normalized to that of b-galactosidase. 
Quantitative reverse transcription-PCR

Statistical analysis
Data are presented as means AE standard error of the mean for at least three independent experiments. Where appropriate, statistical differences were assessed with Student's t-test and plotted using SIGMAPLOT 10.0 software (Systat Software, San Jose, CA, USA).
Results
Interactions between PAR2 and RGS16 or RGS18 in live cells
To determine whether PAR2 interacts with RGS16 in live cells, we performed the BRET assay using PAR2-Venus (PAR2-Ven) and RGS16-Luciferase (RGS16-Luc) expression plasmids. 293T cells were transfected with PAR2-Ven (0-1.5 lg) and RGS16-Luc (0.05 lg) as the acceptor and donor, respectively (Fig. 1A) .
Analysis of BRET signals in the presence or absence of PAR2 peptide agonist, LIGRLO revealed that PAR2 does not interact with RGS16 and the presence of LIGRLO does not promote interactions (Fig. 1A, red line). Next, we determined whether Ga i and Ga o contribute to interactions between PAR2 and RGS16. Interestingly, the additional expression of Ga i induced a significant increase in the BRET signal between the acceptor and donor (Fig. 1A , blue line) while Ga o did not affect this interaction (Fig. 1B, blue line) . In both cases, LIGRLO treatment did not affect the net BRET signal (Fig. 1A,B) . Examination of the effects of other Ga subunits on PAR2-RGS16 interactions disclosed that BRET signals were not altered in the presence of Ga q/11 , Ga 12/13 , or Ga s (Fig. S1 ). In Fig. 1C , each end-point value (condition: expression plasmid concentration, 1.5 lg PAR2-Ven, 0.05 lg RGS16-Luc, and 0.5 lg Ga, in the presence or absence of LIGRLO) of the net BRET signal is presented. Our results suggest that PAR2 binds RGS16 in the presence of Ga i but not other Ga subunits in live cells. We additionally examined whether PAR2 interacts with RGS18 in a Ga-dependent manner.
293T cells transfected with PAR2-Ven (0-1.5 lg), RGS18-Luc (0.1 lg), and Ga (0.5 lg) were subjected to BRET analysis in the presence or absence of LIGRLO (Fig. S2) . No interactions between PAR2 and RGS18 were observed, and neither Ga expression nor LIGRLO treatment promoted interactions between the two proteins. To confirm PAR2-Venus and RGS16-Luc interaction in the presence of Ga i , we additionally transfected with untagged PAR2-FLAG plasmid in the presence of PAR2-Venus, RGS16-Luc and untagged Ga i (Fig. 1D) . BRET signal between PAR2-Venus and RGS16-Luc decreased in untagged PAR2 expression in dose-dependent manner, indicating untagged PAR2 competes with their interaction in the presence of Ga i .
To further confirm PAR2-Ga i -RGS16 interactions, BRET analysis was conducted using Ga i -YFP (2.0 lg) and untagged PAR2 (0-1.0 lg), together with RGS16-Luc (0.15 lg) or RGS18-Luc (0.15 lg) expression plasmids (Fig. 1E,F) . Although the net BRET signals between Ga i -YFP and RGS16-Luc were not altered in the presence of increasing amounts of untagged PAR2, Ga i -YFP and RGS18-Luc signals decreased upon PAR2 expression in a concentration-dependent manner. Application of LIGRLO did not affect interactions under all experimental conditions. In these experimental conditions (Fig. 1E,F) , increased untagged PAR2 expression did not affect the ratio of fluorescence units/luminescence units (Fig. S3) . Based on these results, we propose that PAR2 forms a complex with RGS16 and Ga i and acts as a competitor of interactions between Ga i and RGS18.
Membrane localization of RGS16 in the presence of PAR2 and Ga i
To ascertain whether RGS16 colocalizes with PAR2 and Ga i , cells were cotransfected with plasmids encoding PAR2-Venus and RGS16-HA together with either Ga EE i or Ga EE o , as indicated, and analyzed via immunohistochemistry using antibodies against HA and EE (Fig. 2) . Confocal microscopy revealed that RGS16 mainly localizes to and remains in the cytoplasm, even in the presence of coexpressed PAR2 ( Fig. 2A ). Additional expression of Ga i induced dramatic alterations in subcellular localization of RGS16 from the cytoplasm to plasma membrane, suggesting the formation of a triple complex comprising PAR2, Ga i , and RGS16. In contrast, under PAR2, RGS16, and Ga o coexpression conditions, RGS16 remained in the cytoplasm (Fig. 2B) . We used PCC as a statistic to quantify the extent of colocalization of PAR2 and RGS16 proteins (Fig. 2C) . The closer the PCC value is to zero, the less the correlation between the two (0.5 lg) together with indicated amount of PAR2-FLAG were subjected to BRET analysis. (E, F) 293T cells were transfected with Ga i1 -YFP (2 lg) and RGS16-Luc (0.15 lg, E) or RGS18-Luc (0.15 lg, F) together with untagged PAR2 (0-1.0 lg), and subjected to BRET analysis in the presence and absence of LIGRLO. *P < 0.05, **P < 0.01 and ****P < 0.001, compared to controls. The results are representative of at least three independent experiments.
proteins. As with confocal microscopy observation, the PCC value between PAR2 and RGS16 was significantly increased by Ga i but not Ga o , indicating colocalization of PAR2-RGS16-Ga i in cell membrane. We additionally examined subcellular localization of RGS18 in the presence of PAR2 and Ga i/o proteins via immunocytochemistry of 293T cells expressing PAR2-Venus and RGS18-HA together with either Ga EE i or Ga EE o , as indicated (Fig. S4A,B) . RGS18 was detected mainly in the cytoplasm, regardless of the presence of PAR2 and Ga. PCC value between PAR2 and RGS18 also showed that they were not colocalized in cell membrane (Fig. S4C) . We showed more example images of cellular localization of PAR2, RGS16/ 18, and Ga i/o in Fig. S5 .
RGS16 and RGS18 inhibit PAR2/Ga i/o -mediated signaling
Protease-activated receptor 2 activation induces an increase in ERK1/2 phosphorylation via modulating a Ga i/o -linked pathway [1] . To investigate the effects of RGS16 and RGS18 on ERK1/2 phosphorylation induced by LIGRLO, cells were cotransfected with plasmids encoding PAR2-FLAG and RGS proteins and treated with LIGRLO, as indicated (Fig. 3A) . Cell extracts were subjected to immunoblotting using antibodies against p-ERK and ERK. Band intensity analyses of ERK phosphorylation revealed a significant increase in ERK phosphorylation under conditions of PAR2 expression, which was markedly upregulated by LIGRLO (Fig. 3A,B) . ERK phosphorylation induced by PAR2 was decreased following RGS16 and RGS18 expression (Fig. 3A,C) .
Protease-activated receptor 2 couples with Ga i protein and its activation induces a decrease in the accumulation of intracellular cAMP [16] . To ascertain whether RGS16 and RGS18 alter PAR2/Ga i signaling, we measured the cAMP concentrations in 293T cells transfected with PAR2-FLAG and RGS proteins in the presence and absence of LIGRLO, as indicated (Fig. 3D) . LIGRLO treatment led to the inhibition of cAMP accumulation in PAR2-expressing cells, which was recovered upon expression of RGS16 and RGS18.
In a previous study, we reported that Ga o activity could be measured based on the transcriptional activity of E2F1 in the presence of Necdin, a neutrally differentiated embryonal carcinoma-derived protein that is a downstream target of Ga o [15, 17] . Ga o activation reduces E2F1-mediated transcription, which is accomplished by E2F1 quenching resulting from interactions with Necdin. Although the Ga i protein sequence is highly homologous with that of Ga o , Ga i does not affect Necdin-mediated E2F1 transcription. To examine the effects of PAR2 activation and RGS expression on Ga o /Necdin-mediated E2F1 transactivation, PAR2-FLAG, E2F1, Necdin, Ga o , CMV-bgal, and an E2F4B-Luciferase construct containing an E2F1 binding site upstream of the luciferase gene were cotransfected with either RGS16 or RGS18, as indicated, in 293T cells (Fig. 3E ). Cells were subsequently treated with LIGRLO for 4 min and E2F1-dependent luciferase activity measured. PAR2 activation led to a significant decrease in E2F1 transcription activity, which was recovered upon expression of both RGS16 and RGS18. Taken together, these results indicate that both RGS16 and RGS18 inhibit Ga i/o -mediated PAR2 activation.
Effects of RGS proteins on PAR2/Ga i/o -mediated signaling
We further investigated whether RGS proteins inhibit PAR2/Ga i/o signaling in Neuro2a cells expressing Ga i/o proteins as a normal component [18, 19] . To determine whether PAR2 protein is endogenously expressed in Neuro2a cells, RT-qPCR was performed using a PAR2-specific primer set (Fig. 4A) . PAR2 mRNA levels in Neuro2a cells were similar to those of cells endogenously expressing PAR2, including 293T, HeLa, and MG63 [20] [21] [22] . We further examined whether PAR2-activated ERK signaling is mediated by Ga i/o in cells. To this end, Neuro2a cells were treated with the indicated amounts of LIGRLO for 4 min in the presence of a Ga i/o -specific inhibitor, PTX, and lysates assessed for ERK1/2 phosphorylation (Fig. 4B) . LIGRLO treatment resulted in a significant increase in ERK phosphorylation, which was inhibited upon PTX application, suggesting Ga i/o dependence. Finally, we determined whether RGS proteins inhibit PAR2/Ga i/o -mediated ERK phosphorylation (Fig. 4C,D) . Neuro2a cells were transfected with the indicated isoforms of RGS protein and subsequently treated with LIGRLO for 4 min. Results of band intensity analyses revealed that both RGS16 and RGS18 exerted significant inhibitory effects on ERK phosphorylation, among the RGS proteins examined, suggesting suppression of PAR2/Ga i/omediated signaling in Neuro2a cells.
Protease-activated receptor 2 activation induces Ga i/ o -dependent COX-2 expression in various cell types [23] [24] [25] . To establish whether PAR2 activation induces COX-2 expression in Ga i/o -dependent manner in Neuro2a cells, we pretreated PTX for 24 h before LIGRLO treatment and measured COX-2 expression levels using RT-qPCR (Fig. 4E) . PAR2 activation led to significant enhancement of the level of COX-2, which were inhibited by PTX, suggesting Ga i/o -dependency. We next examine whether PAR2/Ga i/o -mediated COX-2 expression is regulated by RGS proteins. Neuro2a cells endogenously expressing both PAR2 and COX-2 were transfected with RGS16 and RGS18 in the presence of LIGRLO [26] . PAR2-mediated COX-2 expression was inhibited by RGS16 and RGS18 expression, further confirming that RGS16 and RGS18 inhibit PAR2-mediated signaling.
Discussion
In this study, we investigated whether RGS16 and RGS18 interact with PAR2 in live cells to affect PAR2/ Ga i/o -mediated signaling. Our results showed that RGS16 interacts with PAR2 in the presence of Ga i but not other Ga proteins. However, no interactions were observed between RGS18 and PAR2, regardless of the presence or absence of Ga proteins. It has been reported that RGS16 and RGS18 interact with Ga i and inhibit its function [27] [28] [29] . In Fig. 1D , untagged PAR2 expression did not alter BRET signal between Ga i -YFP and RGS16-Luc but it decreased BRET between Ga i -YFP and RGS18-Luc. If untagged PAR2 weakened the binding of Ga i -YFP and RGS16-Luc, their BRET signal would have been decreased as shown by the results of RGS18-Luc (Fig. 1E) . We believe that untagged PAR2 stably associates with Ga i -YFP and RGS16-Luc dimer, but further study will be needed on the mechanism. Based on the results in all BRET data, we consider that PAR2 forms complex with Ga i and RGS16.
Regulators of G protein signaling proteins can interact with GPCRs either directly or indirectly. RGS2 and RGS16 bind the b 2 -adrenergic receptor and regulate Ga s -mediated signaling [30] . RGS2 additionally interacts with the third intracellular loop of a 2 AR and the M1 muscarinic acetylcholine receptor, which induces inhibition of receptor-mediated Ga q signaling [10, 31] . Opioid receptors provide a scaffold platform for binding of RGS4 and Ga proteins [32] . RGS8 directly binds to the N terminus and the third intracellular loop of the M1-muscarinic acetylcholine receptor to regulate receptor-mediated Ga q signaling [33] . In previous studies, RGS8 was shown to inhibit PAR1- ) and subsequently treated with LIGRLO (3 lM) for 4 min. ERK activity was determined by immunoblotting using p-ERK and total ERK antibodies. (C) Neuro2a cells transfected with HA-tagged RGS (1.0 lg) were treated with 10 lM LIGRLO. After 4 min, cells were harvested and ERK activity analyzed via immunoblotting with p-ERK and total ERK antibodies. Expression levels of HA-tagged RGS proteins were determined using immunoblotting with HA antibodies. (D) Densitometry analysis to determine the relative band intensity of p-ERK/ERK. **P < 0.01, compared to controls; # P < 0.05, compared to LIGRLO only treated control. (E) Neuro2a cells were pretreated with PTX (10 ngÁlL À1 ) for 24 h before treatment of LIGRLO (10 lM) for 6 h. The cells transfected with HA-tagged RGS16 and RGS18 (1.0 lg) were treated with LIGRLO. After 6 h, cells were harvested and RT-qPCR analysis performed using primers specific for COX-2. Relative expression levels were normalized to that of GAPDH. *P < 0.05, compared to controls and # P < 0.05, compared to LIGRLO treated condition. Results are representative of at least three independent experiments. mediated Ga i/o signaling by forming a complex with Ga o but not Ga i [15] . RGS2 and RGS4 additionally inhibit PAR1-mediated Ga signaling through interactions with distinct Ga proteins [14] . In this study, RGS16 forms complex with PAR2 and Ga i and inhibits PAR2-mediated signaling. Therefore, we consider that PAR2 functions as scaffolding proteins serving binding platform for RGS16 and Ga i as adrenergic, acetylcholine, opioid receptor, and PAR1.
Both RGS16 and RGS18 proteins suppressed PAR1-mediated Ga i/o downstream signaling events, including ERK phosphorylation, adenylyl cyclase activity, and E2F1 transcriptional activity in our experiments. A number of reports have shown that RGS16 interacts with Ga i/o and abolishes its signaling [34, 35] . Likewise, RGS18 interacts with Ga i and accelerates its intrinsic GTPase activity [36, 37] . We propose that the trimeric PAR2-Ga i -RGS16 complex inhibits PAR2-activated Ga i signaling, whereas RGS16 suppresses Ga o signaling without interacting with PAR2. Additionally, our results suggest that RGS18 blocks PAR2-mediated Ga i/o signaling through interactions with Ga, regardless of the role of PAR2.
Bioluminescence resonance energy transfer results were confirmed via a colocalization assay with immunohistochemistry. The BRET signal was increased in the presence of PAR2, RGS16, and Ga i relative to that in the presence of PAR2/RGS16, PAR2/RGS16/Ga o , PAR2/ RGS18, and PAR2/RGS18/Ga i/o . In the colocalization assay, the cytoplasmic RGS16 protein translocated to the plasma membrane in the presence of PAR2 and Ga i . RGS16 only localized in the membrane under these conditions. These results are consistent with our previous findings [15] , whereby RGS8 was also found to localize in the membrane in the presence of PAR1 and Ga o in the form of a trimeric complex. Subcellular distribution of RGS proteins is dynamic in regulating G protein and other signaling molecules. Despite common localization of interacting partners in the plasma membrane, many RGS proteins have been detected in the cytoplasm and nucleus [38, 39] . Membrane localization of RGS proteins is attributable to G protein and GPCR activation [40] [41] [42] , protein structures [43] [44] [45] , and interactions with scaffolding proteins [46] [47] [48] .
Protease-activated receptor 2 is implicated in various cellular (patho)physiologies, including inflammation, pain, and cancer. Interestingly, PAR2 acts as a tumor suppressor in epidermal skin tumors [49] and is conversely involved in the progression of many tumor types by promoting invasion and metastasis [50] . PAR2 also plays an important role in nociceptive transmission, and therefore, its antagonism contributes to hyperalgesia [51] [52] [53] . PAR2 signaling has a significant impact on the induction and maintenance of persistent pain, especially in inflammatory, neuropathic, and cancer conditions [54] . Activation of PAR2 triggers the release of numerous inflammatory mediators, such as prostaglandin-, substance P-, and calcitonin-related gene peptides or cytokines, in turn, inducing or modulating pain perception [55] [56] [57] , signifying an important role in pathogenesis. Accordingly, antagonism of PAR2 activation presents a promising therapeutic strategy for PAR2-related pathogenesis. In this respect, our findings that RGS16 and RGS18 inhibit PAR2/Ga i/omediated signaling may yield valuable information for therapeutic purposes.
Increased COX-2 expression is observed in various cancer types, including breast and colorectal cancer [25, 58] . COX-2 stimulates the prostaglandin E 2 pathway, which induces tumor growth, invagination, and inhibition of apoptosis [25] . In our experiments, RGS16 and RGS18 inhibited PAR2-mediated COX-2 expression, supporting a possible novel role of RGS in controlling cancer cell spread.
In conclusion, the current study involved the investigation of the binding properties of PAR2, Ga, and RGS proteins, including RGS16 and RGS18, in live cells. We additionally determined the effects of RGS proteins on PAR2-mediated Ga i/o functions. RGS16 formed a complex with PAR2 and Ga i and inhibited PAR2/Ga i -mediated signaling. Additionally, RGS16 inhibited PAR2/Ga o -mediated signaling without binding to PAR2. Experiments with RGS18 revealed suppression of PAR2/Ga i/o -mediated signaling with no interactions with PAR2. Our findings suggest that PAR2 selectively forms a scaffold platform with RGS and Ga proteins and modulates their downstream signaling. To our knowledge, this is the first study to show that RGS16 and RGS18 proteins inhibit PAR2-mediated signaling. The collective results provide novel insights into the molecular mechanisms by which GPCR, RGS, and Ga form functional complexes within cells.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. Fig. S1 . Interactions between PAR2 and RGS16 with Ga proteins, except Ga i/o , in living cells. 
